Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

4.44GBp
28 Apr 2017
Change (% chg)

-0.11 (-2.42%)
Prev Close
4.55
Open
4.58
Day's High
4.58
Day's Low
4.44
Volume
3,437,944
Avg. Vol
4,307,953
52-wk High
6.12
52-wk Low
2.98

OXB.L

Chart for OXB.L

About

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D... (more)

Overall

Beta: 0.60
Market Cap(Mil.): £140.52
Shares Outstanding(Mil.): 3,088.31
Dividend: --
Yield (%): --

Financials

  OXB.L Industry Sector
P/E (TTM): -- 58.07 30.12
EPS (TTM): -0.01 -- --
ROI: -38.56 0.23 13.28
ROE: -141.57 6.18 14.44

BRIEF-Oxford Biomedica notes acceptance by FDA of a biologics license application filing for CTL019

* Oxford Biomedica notes acceptance by FDA of a biologics license application (BLA) filing for CTL019

Mar 30 2017

BRIEF-Oxford biomedica says Trovax shown to induce beneficial anti-tumour immune responses

* Cyclophosphamide and Trovax independently shown to induce highly beneficial anti-tumour immune responses

Feb 24 2017

BRIEF-Oxford Biomedica inks strategic alliance with Orchard Therapeutics

* Oxford Biomedica announces a strategic alliance with Orchard Therapeutics

Nov 29 2016

More From Around the Web

Earnings vs. Estimates